The American Journal of Managed Care

Dr Joshua Sabari: “Tissue Is the Issue” in NGS for EGFR Exon 20 Insertion+ NSCLC

Joshua Sabari, MD, assistant professor of medicine, Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, discusses topics involving next generation sequencing (NGS) to ...
The American Journal of Managed Care

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
Cure Today

Targeting the 'Typos' for Lung Cancer Harboring Rare Genetic Mutations

New treatments may stall lung cancer progression in patients with EGFR exon 20 insertion mutations. After spending a warm spring day in 2022 pulling weeds and planting perennials, Renata Muller, 66, ...
clinicaladvisor.com

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
Cure Today

Standard Treatment May Not Be Best for Exon 20-Mutant Lung Cancer

Rybrevant outperformed other therapies for patients with exon 20 insertion-mutant, advanced non-small cell lung cancer in a clinical trial, highlighting the importance of personalized medicine.

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
Monthly Prescribing Reference

Rybrevant Combo Approved as First-Line Tx for NSCLC With EGFR Exon 20 Insertion Mutations

Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
MedPage Today

Novel TKI, Sunvozertinib, in Platinum-Pretreated NSCLC Patients With Exon 20 Insertion Mutations

Exon 20 insertion mutations in non-small cell lung cancers have been a therapeutic challenge, and thus new agents targeting exon 20 mutations are a welcome addition. The study by James Chih-Hsin Yang ...
Nasdaq

Cullinan Therapeutics to Present Positive REZILIENT1 Study Results of Zipalertinib for NSCLC at 2025 ASCO Annual Meeting

Cullinan Therapeutics, Inc. announced that it will present results from the REZILIENT1 study of zipalertinib, a treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion ...
Nasdaq

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR ...

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...
WebMD

FDA OKs First-of-Its-Kind Lung Cancer Pill

July 7, 2025 – The FDA has granted quick approval to a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC). The drug, called sunvozertinib and sold as Zegfrovy ...